The second stage of clinical trials of a coronavirus vaccine in the form of a nasal spray, developed by specialists of the National Research Center for Epidemiology and Microbiology named after N.F. Gamalei until it started. The director of the center Alexander Gintsburg told reporters about it.
“Research is allowed, but not started,” – said the scientist in an interview with TASS.
Alexander Gintsburg clarified that funding has not yet been allocated for the second stage of drug testing.
Recall, as the website kp.ru wrote, in the St. Petersburg Research Institute of Influenza named after A.A. Smorodintseva are developing a unique vaccine against the SARS-CoV-2 coronavirus, which, unlike other similar drugs, will be administered internally – that is, into the nose. It will not be an injection solution, but a spray. It has already been tested on animals, and trials with volunteers may begin in late 2021 or early 2022.